Search Within

Myeloma

Formats
  1. Meeting Abstract (557)
  2. Journal Article (368)
  3. Review (37)
  4. Research Letter (21)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (7)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (1016)
  2. Department of Medicine (1016)
  3. Hematologic Malignancies, Division of (1016)
  4. Hematologic Malignancies Research (669)
  5. Survivorship Research (374)
  6. Sloan Kettering Institute Postdocs (306)

More Groups

People
  1. Alexander Lesokhin (381)
  2. Hani Hassoun (339)
  3. Carl Landgren (336)
  4. Sham Mailankody (297)
  5. Malin Hultcrantz (274)
  6. Heather Landau (249)

More People

Years
  1. 2025 (28)
  2. 2024 (82)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (317)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (86)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (24)

More Publications

Publishers
  1. American Society of Hematology (340)
  2. Elsevier Inc. (160)
  3. American Society of Clinical Oncology (88)
  4. Nature Publishing Group (87)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (1016)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Presalvage international staging system stage and other important outcome associations in CD34(+)-selected allogeneic hematopoietic stem cell transplantation for multiple myelomas
    Journal Article

    Bryant, A. R.; Hilden, P.; Giralt, S.; Chung, D. J.; Maloy, M.; Landau, H.; Landgren, O.; Scordo, M.; Shah, G.; Smith, E. L.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors
    Journal Article

    Hultcrantz, M.; Modlitba, A.; Vasan, S. K.; Sjölander, A.; Rostgaard, K.; Landgren, O.; Hjalgrim, H.; Ullum, H.; Erikstrup, C.; Kristinsson, S. Y.; more...
    Thrombosis Research (2020)

    Fulltext@MSK | Save
  • Monoclonal gammopathies
    Book Section

    Murata, K.; McCash, S.; Landgren, C. O.
    In Rich, R. R.; Fleisher, T. A.; Shearer, W. T.; Schroeder, H. W. Jr; Frew, A. J.; Weyand, C. M (Eds.) Clinical Immunology: Principles and Practice. 5th ed (2019)

    Fulltext@MSK | Save
  • Peripheral neuropathy in MGUS and progression to amyloid light-chain amyloidosis: A population-based study including 15,351 MGUS cases
    Meeting Abstract

    Rognvaldsson, S.; Turesson, I.; Bjorkholm, M.; Landgren, O.; Kristinsson, S. Y.
    Blood (2019)

    Fulltext@MSK | Save
  • A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis
    Meeting Abstract

    Sanchez, L.; Landau, H. J.; Rosenbaum, C. A.; Abrahams, A.; Chin, C.; Liotta, B.; Agudo, N.; Ramnath, S.; Hoover, E.; Rahman, H.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Difference in involved and uninvolved free light chain (dFLC) of less than 1mg/DL early post risk adapted melphalan and autologous stem cell transplantation (RA-ASCT) predicts renal response at 1 year in light chain (AL) amyloidosis
    Meeting Abstract

    Purvey, S.; Seier, K.; Devlin, S. M.; Ruiz, J. D.; Maloy, M. A.; Shah, G. L.; Hassoun, H.; Giralt, S. A.; Landau, H. J.
    Blood (2019)

    Fulltext@MSK | Save
  • Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a phase I study of PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Raje, N. S.; Jakubowiak, A.; Gasparetto, C.; Cornell, R. F.; Krupka, H. I.; Navarro, D.; Forgie, A. J.; Udata, C.; Basu, C.; Chou, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM)
    Meeting Abstract

    Manasanch, E. E.; Jagannath, S.; Lee, H. C.; Patel, K. K.; Graham, C.; Kaufman, G. P.; Thomas, S. K.; Iyer, S.; Mailankody, S.; Korde, N.; more...
    Blood (2019)

    Fulltext@MSK | Save